View details of this raise on Seedstage

Alameda, CA

Developing next-generation intranasal naloxone for opioid overdose.

• Intranasal Drug Development: EmerRx BioPharma is developing intranasal drugs that deliver intravenous-like speed and efficacy without needles.
• Lead Product EMRX-101: EMRX-101 is a naloxone nasal spray designed to reverse opioid overdoses with faster onset and longer duration.
• Proprietary Delivery System: The company uses a dual-compartment intranasal delivery device to enhance drug absorption and reliability.
• Pipeline Expansion: EmerRx plans to develop additional intranasal drugs, including epinephrine and ketamine, for emergency care.
• Strategic Partnerships: The company aims to out-license or sell its programs to pharmaceutical partners after clinical validation.

EmerRx BioPharma is developing intranasal emergency and therapeutic drugs that aim to deliver the speed and efficacy of intravenous treatments without the need for a needle. The company’s lead product, EMRX-101, is a preclinical naloxone nasal spray system designed to reverse opioid overdoses with a faster onset and longer duration than existing alternatives. By utilizing a proprietary dual-compartment intranasal delivery device and an optimized buffering formulation, EMRX-101 seeks to enhance absorption across the nasal mucosa, improving reliability and reducing the need for repeat dosing.

EmerRx BioPharma was founded by a team of experienced biotech professionals to address the urgent opioid overdose crisis. The company has filed a provisional patent, established a collaboration with a bioanalytical research lab, and secured early-stage funding. In addition to EMRX-101, EmerRx plans to expand its pipeline with intranasal emergency and therapeutic drug candidates, including epinephrine and ketamine. These programs aim to broaden EmerRx’s reach across multiple high-impact emergency care and neuropsychiatric applications. The company’s business model focuses on advancing drug candidates through early-stage clinical development, with the goal of out-licensing or selling its programs to strategic pharmaceutical partners following clinical proof-of-concept.

Company Info

EmerRx Biopharma is developing next-generation intranasal naloxone with intravenous-like speed and efficacy, addressing a critical gap in opioid overdose reversal.

EmerRx BioPharma is focused on developing intranasal emergency and therapeutic drugs that offer the speed and efficacy of intravenous treatments without the need for needles. Their flagship product, EMRX-101, is a preclinical naloxone nasal spray system designed to reverse opioid overdoses with a faster onset and longer duration than current alternatives. By utilizing a proprietary dual-compartment intranasal delivery device combined with an optimized buffering formulation, EMRX-101 aims to enhance absorption across the nasal mucosa, improving reliability and reducing the need for repeat dosing.

In addition to EMRX-101, EmerRx is expanding its pipeline to include other intranasal emergency and therapeutic drug candidates, such as intranasal epinephrine and ketamine. These future programs are intended to broaden EmerRx’s reach across multiple high-impact emergency care and neuropsychiatric applications. The company’s business model focuses on advancing drug candidates through early-stage clinical development, with plans to out-license or sell its programs to strategic pharmaceutical partners after clinical proof-of-concept.